timothy sykes logo

Stock News

FDA Approval Boosts Future Prospects for Aquestive Therapeutics

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 9/20/2025, 12:22 pm ET 9/20/2025, 12:22 pm ET | 6 min 6 min read
FDA Approval Boosts Future Prospects for Aquestive Therapeutics Thumbnail

Aquestive Therapeutics Inc.’s stocks have been trading up by 15.34 percent, driven by promising FDA designations and positive trial results.

Healthcare industry expert:

Analyst sentiment – positive

  1. Market Position & Fundamentals: Aquestive Therapeutics (AQST) is struggling with significant profitability challenges marked by negative margins across the board, including an EBIT margin of -134.2% and a profit margin on total operations of -147.38%. The company’s revenue trajectory over the past five years shows decline rates of -5.73%, resulting in earnings pressures not mitigated by positive cash flow. The firm’s financial strength, exemplified by a high current ratio of 3.5, indicates good short-term solvency, but poor management effectiveness sets the firm back with return on assets at a troubling -63.95%. Operating in a leveraged position with negative equity, AQST operates at significant risk, highlighting their precarious market stance.

  2. Technical Analysis & Trading Strategy: Recent weekly price action for AQST demonstrates volatility, with a recent closing price of $5.6978 on September 19. The stock has shown varied support around $4.87, observed on September 16, and resistance levels potentially forming above $5.67, denoting an upward trend reinforced by increased trading volumes post-positive FDA news. As momentum builds, a price surge past the $6.00 level could follow on continued optimism and increased investor activity, suggesting a trading strategy focused on buying into this trend with tight stop-loss orders below $5.00 to manage downside risk effectively.

  3. Catalysts & Outlook: Recent announcements by AQST detail that its Anaphylm Sublingual Film is making promising progress with the FDA not requiring an advisory committee meeting, enhancing probabilities for a timely approval by January 2026. Market confidence materialized with considerable stock price surges, outpacing healthcare benchmarks, driven by brokerage price target upgrades to $8-$10. This asset is poised for gains if the approval process remains on track, suggesting a potential catalyzed breakout towards analysts’ higher price targets. With strong prospects hinged on product approval, AQST’s outlook remains positive, and the stock is positioned to breach resistance, moving towards the target range supported by favorable analyst ratings and strategic market approaches.

  • LifeSci Capital initiates coverage with an Outperform rating and sets a price target of $10, reflecting investor confidence in the company’s growth trajectory.

  • Oppenheimer ups their price target for the company to $8, citing favorable developments around the FDA decision, spurring a dramatic 43.77% rise in stock price.

Candlestick Chart

Weekly Update Sep 15 – Sep 19, 2025: On Saturday, September 20, 2025 Aquestive Therapeutics Inc. stock [NASDAQ: AQST] is trending up by 15.34%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

The financial health of Aquestive Therapeutics is currently underscored by a range of fluctuating metrics and market movements. Recent earnings show some vulnerabilities, particularly a significant dip in operating revenue, sitting at $10.003M with high total expenses at $21.37M. Although gross margins are positive at 61.1%, profitability margins face adverse pressures with a net income slipping to -$13.548M from continuing operations.

The stock exhibited pronounced volatility as evidenced by recent market activity, showcasing highs peaking at $5.72 and lows touching a modest $4.86. Comparing Q2 figures, systemic issues such as a high price-to-sales ratio at 11.16 and a total debt deteriorating the company’s book value, prompts concerns. Notably, AQST’s stock surged in response to strategic FDA news alongside raised investment ratings, indicating favorable investor sentiment and resultant stock upticks.

More Breaking News

Given the announcement regarding Anaphylm’s FDA approval pathway, shared key ratios and fluctuating liquidity reveal room for an upside if approval timelines align seamlessly with current projections, potentially stabilizing the company’s market positions and fostering long-term growth.

Conclusion

Aquestive Therapeutics stands at the cusp of significant growth driven by strategic FDA approvals and elevated market expectations. Strong endorsements from financial powerhouses such as LifeSci Capital and Oppenheimer accentuate potential upside avenues, extending beyond current price inflations. While traders are drawn to the surge in stock valuation, it’s prudent to remember the insight of millionaire penny stock trader and teacher Tim Sykes, who says, “There is always another play around the corner; don’t chase just because you feel FOMO.” While historical fiscal challenges remain apparent, the evidenced surge in stock valuation speaks volumes about market confidence in the company’s trajectory. Continued shareholder support, buoyed by FDA progress and strategic positioning in the treatment landscape, craft a convincing narrative for the firm’s elevation on the market stage. With momentous developments poised to influence coming quarters, the company’s actions resonate as a telling testament to its commitment to delivering sustainable value to its stakeholders.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”